Role of fibroblast growth factor receptor 4 in cancer

被引：33

作者：

Tang, Shuya ^{[1
]}

Hao, Yilong ^{[1
]}

Yuan, Yao ^{[1
]}

Liu, Rui ^{[1
]}

Chen, Qianming ^{[1
]}

机构：

[1] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China

来源：

CANCER SCIENCE | 2018年 / 109卷 / 10期

基金：

中国国家自然科学基金;

关键词：

aberrant signaling pathway; cancer; dysregulation; fibroblast growth factor receptor 4; therapeutic target; TO-MESENCHYMAL TRANSITION; FGFR4; BREAST; MICE; FAMILY; LIVER; GENE; POLYMORPHISM; SPECIFICITY; INHIBITOR;

D O I：

10.1111/cas.13759

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fibroblast growth factor receptors (FGFR) play a significant role in both embryonic development and in adults. Upon binding with ligands, FGFR signaling is activated and triggers various downstream signal cascades that are implicated in diverse biological processes. Aberrant regulations of FGFR signaling are detected in numerous cancers. Although FGFR4 was discovered later than other FGFR, information on the involvement of FGFR4 in cancers has significantly increased in recent years. In this review, the recent findings in FGFR4 structure, signaling transduction, physiological function, aberrant regulations, and effects in cancers as well as its potential applications as an anticancer therapeutic target are summarized.

引用

页码：3024 / 3031

页数：8

共 44 条

[1] Acetyl-CoA Carboxylase 2-/- Mutant Mice are Protected against Fatty Liver under High-fat, High-carbohydrate Dietary and de Novo Lipogenic Conditions
Abu-Elheiga, Lutfi
Wu, Hongmei
Gu, Ziwei
Bressler, Rubin
Wakil, Salih J.
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (15) : 12578 - 12588
[2] Bange J, 2002, CANCER RES, V62, P840
[3] The FGF family: biology, pathophysiology and therapy
Beenken, Andrew
Mohammadi, Moosa
[J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (03) : 235 - 253
[4] The promises and pitfalls of RNA-interference-based therapeutics
Castanotto, Daniela
Rossi, John J.
[J]. NATURE, 2009, 457 (7228) : 426 - 433
[5] Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models
Desnoyers, Lr
Pai, R.
Ferrando, Re
Hotzel, K.
Le, T.
Ross, J.
Carano, R.
D'Souza, A.
Qing, J.
Mohtashemi, I.
Ashkenazi, A.
French, Dm
[J]. ONCOGENE, 2008, 27 (01) : 85 - 97
[6] Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models
French, Dorothy M.
Lin, Benjamin C.
Wang, Manping
Adams, Camellia
Shek, Theresa
Hoetzel, Kathy
Bolon, Brad
Ferrando, Ronald
Blackmore, Craig
Schroeder, Kurt
Rodriguez, Luis A.
Hristopoulos, Maria
Venook, Rayna
Ashkenazi, Avi
Desnoyers, Luc R.
[J]. PLOS ONE, 2012, 7 (05): : e36713
[7] Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor
Frullanti, Elisa
Berking, Carola
Harbeck, Nadia
Jezequel, Pascal
Haugen, Aage
Mawrin, Christian
Parise, Orlando, Jr.
Sasaki, Hidefumi
Tsuchiya, Norihiko
Dragani, Tommaso A.
[J]. EUROPEAN JOURNAL OF CANCER PREVENTION, 2011, 20 (04) : 340 - 347
[8] AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
Gavine, Paul R.
Mooney, Lorraine
Kilgour, Elaine
Thomas, Andrew P.
Al-Kadhimi, Katherine
Beck, Sarah
Rooney, Claire
Coleman, Tanya
Baker, Dawn
Mellor, Martine J.
Brooks, A. Nigel
Klinowska, Teresa
[J]. CANCER RESEARCH, 2012, 72 (08) : 2045 - 2056
[9] Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins
Gotoh, Noriko
[J]. CANCER SCIENCE, 2008, 99 (07) : 1319 - 1325
[10] Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer
Gowardhan, B
Douglas, DA
Mathers, ME
McKie, AB
McCracken, SRC
Robson, CN
Leung, HY
[J]. BRITISH JOURNAL OF CANCER, 2005, 92 (02) : 320 - 327

← 1 2 3 4 5 →